文献速递脊柱关节炎其他结缔组织病

银屑病及银屑病关节炎/强直性脊柱炎患者启用IL-17抑制剂后的炎症性肠病风险:法国全国人群研究

Risk of Inflammatory Bowel Disease in Patients With Psoriasis and Psoriatic Arthritis/Ankylosing Spondylitis Initiating Interleukin-17 Inhibitors: A Nationwide Population-Based Study Using the French National Health Data System.
PubMed 文献 · Arthritis Rheumatol · 2022-01-01

基于法国国家健康数据系统的全国队列研究,纳入2016-2019年新启用IL-17抑制剂、阿普司特或依那西普的银屑病合并银屑病关节炎/强直性脊柱炎成人患者。倾向评分加权后,IL-17抑制剂较阿普司特显著增加IBD风险(加权HR 3.8,95%CI 2.1-6.8),但与依那西普相比无差异(加权HR 0.8,95%CI 0.5-1.2)。

要点

  • IL-17抑制剂较阿普司特显著增加IBD风险,加权HR 3.8(95%CI 2.1-6.8)。
  • IL-17抑制剂与依那西普相比IBD风险无差异,加权HR 0.8(95%CI 0.5-1.2)。
  • 多数IBD病例发生在暴露6个月之后。

核心结论

  • 在基础疾病严重程度相同时,银屑病合并银屑病关节炎/强直性脊柱炎患者启用IL-17抑制剂后IBD风险不高于启用依那西普者。

研究设计与样本

  • 法国全国队列研究,使用法国国家健康数据系统数据库。
  • 纳入2016-2019年新启用IL-17抑制剂的银屑病合并银屑病关节炎/强直性脊柱炎成人患者,对照为新启用阿普司特或依那西普且未接受IL-17抑制剂者。
  • 随访截止2019年9月30日,采用倾向评分加权Cox和Fine-Gray比例风险模型进行时间-事件分析。
  • 共纳入16793例新IL-17抑制剂使用者、20556例新阿普司特使用者和10294例新依那西普使用者。

主要发现

  • IBD共发生132例:新IL-17抑制剂使用者72例(0.43%),新阿普司特使用者11例(0.05%),新依那西普使用者49例(0.48%)。
  • 多数IBD病例发生在暴露6个月之后(三组分别为82%、55%、76%)。
  • 倾向评分加权后,IL-17抑制剂较阿普司特显著增加IBD风险(加权HR 3.8,95%CI 2.1-6.8)。
  • IL-17抑制剂与依那西普相比IBD风险无差异(加权HR 0.8,95%CI 0.5-1.2)。

关键数值与推荐

  • 主要终点为IL-17抑制剂暴露相较于其他治疗发生IBD的风险,采用倾向评分加权Cox和Fine-Gray比例风险模型分析。
  • 新IL-17抑制剂使用者平均年龄48.4±13岁、男性45%;新阿普司特使用者平均年龄52.6±15岁、男性54%;新依那西普使用者平均年龄46.3±15岁、男性44%。
  • 新IL-17抑制剂使用者和新依那西普使用者较新阿普司特使用者接受了更多针对基础疾病的生物制剂治疗。

临床怎么用

  • 对银屑病合并银屑病关节炎/强直性脊柱炎患者,启用IL-17抑制剂时IBD风险与依那西普相当,但需注意多数IBD事件发生在暴露6个月后。
  • 与阿普司特相比IL-17抑制剂的IBD风险较高,选择治疗时应结合患者基础疾病严重程度综合评估。

局限性

  • 结果需在其他大型银屑病合并银屑病关节炎/强直性脊柱炎患者研究中确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate whether the initiation of treatment with an interleukin-17 inhibitor (IL-17i) in real life is associated with a higher risk of inflammatory bowel disease (IBD) in patients who had both psoriasis (PsO) and psoriatic arthritis (PsA)/ankylosing spondylitis (AS). METHODS: This nationwide cohort study was conducted using the French National Health Data System database. All adult patients with PsO and PsA/AS who were identified as having newly initiated treatment with an IL-17i during 2016-2019 were included. As controls, patients with PsO and PsA/AS who had newly initiated either 1) apremilast or 2) etanercept (ETN) during this period but had not received IL-17i were included. The follow-up end date was September 30, 2019. The primary end point was the risk of occurrence of IBD associated with exposure to an IL-17i compared to exposure to the other treatments, as determined in a time-to-event analysis with propensity score-weighted Cox and Fine-Gray proportional hazards models. RESULTS: The study included a total of 16,793 new IL-17i users (mean ± SD age 48.4 ± 13 years, 45% men), 20,556 new apremilast users (age 52.6 ± 15 years, 54% men), and 10,294 new ETN users (age 46.3 ± 15 years, 44% men). New IL-17i users and new ETN users had received more biologics for their underlying disease compared to new apremilast users. IBD occurred in 132 patients: 72 new IL-17i users (0.43%), 11 new apremilast users (0.05%), and 49 new ETN users (0.48%). Most IBD cases occurred after 6 months of exposure (82%, 55%, and 76%, respectively). After propensity score weighting, the risk of IBD was significantly greater among patients initiating an IL-17i compared to those initiating apremilast (weighted hazard ratio [HR] 3.8 [95% confidence interval (95% CI) 2.1-6.8]). No difference in the risk of IBD between new IL-17i users and new ETN users was observed (weighted HR 0.8 [95% CI 0.5-1.2]). CONCLUSION: Patients with PsO and PsA/AS who initiate treatment with an IL-17i do not have a higher risk of developing IBD when compared to patients initiating ETN who display the same severity of underlying disease. These results need to be confirmed in other large studies of patients with PsO and PsA/AS.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Penso L, Bergqvist C, Meyer A, et al. Risk of Inflammatory Bowel Disease in Patients With Psoriasis and Psoriatic Arthritis/Ankylosing Spondylitis Initiating Interleukin-17 Inhibitors: A Nationwide Population-Based Study Using the French National Health Data System. Arthritis Rheumatol. 2022. PMID: 34279061. doi:10.1002/art.41923

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。